Dr.MetabolicMD said:SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk.
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 4 of 5 diagnostic criteria to meeting ZERO after 12 months of treatment.
The 5 criteria (and my journey):
- Waist circumference: 51" → 35" ✅ Resolved
- Triglycerides: 277 → 102 ✅ Resolved
- HDL: 35 → 59 ✅ Resolved
- Blood pressure: 147/95 → 120/74 ✅ Resolved
- Fasting glucose: 127 → 87 ✅ Resolved
Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.